TGFBR2 and metastatic prostate carcinoma: Similarly, it has been reported that genetic polymorphism in the promoter region of TGFBR2 gene coding TGF-βRII was associated with Gleason score and risk of early relapse after ADT among patients with both non-metastatic and metastatic prostate cancer (25).